Adipotide

Adipotide is a lab-made compound explored for reducing body fat. It works by affecting blood flow to fat tissue, helping the body break it down naturally. It is still being studied and has not been tested or approved for regular use.

Description

• Adipotide (FTP-1) is a synthetic peptide designed to selectively target and reduce white fat tissue.
• It acts by cutting off blood supply to fat cells, leading to apoptosis (cell death) and natural clearance.
• Developed as a non-hormonal research approach to obesity and metabolic disorders.

How It Works

• Targets prohibitin receptors on the surface of blood vessels that supply white adipose tissue.
• Delivers a pro-apoptotic sequence that induces vessel death, causing fat tissue reduction.
• Does not influence appetite or hormonal systems such as insulin or leptin.

Documented Effects

• Reduced body weight and fat mass in obese primate studies.
• Improved insulin sensitivity and metabolic parameters.
• Demonstrated reversible fat loss upon treatment discontinuation.

Theoretical Effects

• Potential adjunct for obesity, insulin resistance, or fatty liver research.
• Non-stimulant, vascular-based mechanism distinct from metabolic peptides.
• Not yet tested for long-term safety or human clinical efficacy.

Pharmacokinetics

• Half-life: approximately 4–6 hours based on preclinical animal data.
• Peak concentration: observed within 1–2 hours after subcutaneous administration.
• Steady-state: reached after 2–3 days of consistent daily dosing.

Duration of Effects

• Active effects on fat reduction may last 6–10 hours after each dose.
• Visible body composition changes can persist for days to weeks after discontinuation.
• Most preclinical effects reverse gradually within several weeks post-cycle.

Reconstitution

• Use only bacteriostatic water to mix the lyophilized powder.
• Example vial: 5 mg of Adipotide
• Choose reconstitution volume based on dosing convenience:
  • 1 mL water → 5 mg/mL → 0.5 mg per 10 units
  • 2 mL water → 2.5 mg/mL → 0.25 mg per 10 units
  • 4 mL water → 1.25 mg/mL → 0.125 mg per 10 units
• Swirl gently to dissolve; avoid shaking.
• Refrigerate reconstituted solution (2–8 °C). Use within ~21 days for best stability.

Injectable Dosage Overview (First-Time Use)

Typical Starting Dose

• Research reference: ~0.25 mg per kg subcutaneous (SC) once daily.
• Example: 20 mg daily for an 80 kg research subject.

Common Therapeutic Range

• Range: 0.25–1 mg/kg SC daily in preclinical protocols.
• Duration: typically 2–4 weeks of use per cycle.

Maximum Daily Dose

• Up to ~1 mg/kg/day tested in primate models.
• Higher exposure associated with transient renal strain; not recommended.

Standard Cycle Length

• 2–4 weeks active phase followed by 2–3 weeks off.

Clinical Notes

• Typically studied via subcutaneous injection once per day under laboratory conditions.
• No tapering is required, but gradual cessation helps monitor post-cycle effects.
• Stacking with other fat-targeting agents is not recommended due to renal load concerns.
• Stable for about 21 days when refrigerated (2–8°C). Protect from light and heat. Avoid freezing.

Safety Notes (First-Time Use)

• Ensure hydration and renal function monitoring during research cycles.
• Possible transient effects: nausea, fatigue, dehydration.
• Preclinical only — no human approval for medical or cosmetic use.